Another study revealed that a high T effector gene signature expression in tumor tissues at baseline was associated with improved overall response rate and PFS of RCC patients treated with anti-PD-L1 and anti-VEGF antibodies [48]. The gene discussed is VEGFA; the disease is neoplasm.